

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

RECKITT BENCKISER
PHARMACEUTICALS INC., RB
PHARMACEUTICALS LIMITED, and
MONOSOL RX, LLC,

Plaintiffs,

v.

DR. REDDY'S LABORATORIES S.A. and
DR. REDDY'S LABORATORIES, INC.,

Defendants.

C.A. No. 14-01451-RGA

DEFENDANTS' NOTICE OF CROSS-APPEAL

PLEASE TAKE NOTICE that, pursuant to Federal Rule of Appellate Procedure 4(a)(3) Defendants Dr. Reddy's Laboratories S.A. and Dr. Reddy's Laboratories, Inc. (collectively, "DRL"), cross-appeal to the United States Court of Appeals for the Federal Circuit from all aspects of the Court's Final Judgment (D.I. 315) resolved adversely to DRL, including all prior interlocutory orders, rulings, decisions, and subsidiary findings resolved adversely to DRL.

Without limitation, DRL specifically appeals from:

Aspects of the Final Judgment holding not invalid claims 1, 4, 5, 8 and 9 of U.S. Patent No. 8,017,150; claims 62-65, 69, 71, and 73 of U.S. Patent No. 8,603,514; and claim 24 of U.S. Patent No. 8,900,497;

The corresponding portions of the Trial Opinion dated August 31, 2017 (D.I. 313);

Aspects of the Markman Order (D.I. 179) construing the terms

- "said matrix having a substantially uniform distribution of said at least one active" and "said matrix having a substantially uniform distribution of said

active” in claims 1, 26, 27, and 30 of the ’497 patent,

- “to maintain said substantially uniform distribution of said at least one active by locking-in or substantially preventing migration of said at least one active” and “to maintain said substantially uniform distribution of said active by locking-in or substantially preventing migration of said active” in claims 1, 26, 27, and 30 of the ’497 patent,
- “rapidly” in claims 1, 26, 27, and 30 of the ’497 patent,
- “a taste-masking agent coated or intimately associated with said particulate” in claims 1 and 28 of the ’514 patent, and
- “said matrix has a viscosity sufficient to aid in substantially maintaining non-self-aggregating uniformity of the active in the matrix” in claims 1, 16, 28, 48, 58, and 62 of the ’514 patent; and

The corresponding portions of the Memorandum Opinion on claim construction dated June 28, 2016 (D.I. 175).

Included herewith is payment of the filing fee (\$5.00) and the docketing fee (\$500.00) as required by 28 U.S.C. § 1917, Federal Circuit Rule 52(a)(3)(A), Federal Rule of Appellate Procedure 3(e), and the United States District Court for the District of Delaware fee schedule (effective December 1, 2013).

Dated: October 27, 2017

BAYARD, P.A.

OF COUNSEL:

/s/ Stephen B. Brauerman

Elaine Herrmann Blais
Robert Frederickson, III
Molly Grammel
Alexandra Lu
Kathryn Kosinski
GOODWIN PROCTER LLP
100 Northern Avenue
Boston, MA 02210
(617) 570-1205
eblais@goodwinlaw.com
rfrederickson@goodwinlaw.com
mgrammel@goodwinlaw.com
alu@goodwinlaw.com
kkosinski@goodwinlaw.com

Richard D. Kirk (rk922)
Stephen B. Brauerman (sb4952)
Sara E. Bussiere (sb5725)
222 Delaware Avenue, Suite 900
P.O. Box 25130
Wilmington, DE 19899
(302) 655-5000
rkirk@bayardlaw.com
sbrauerman@bayardlaw.com
sbussiere@bayardlaw.com

*Attorneys for Defendants Dr. Reddy's
Laboratories S.A. and Dr. Reddy's Laboratories,
Inc.*

Robert V. Cerwinski
Ira Jay Levy
GOODWIN PROCTER LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018
(212) 813-8800
rcerwinski@goodwinlaw.com
ilevy@goodwinlaw.com

John Coy Stull
GOODWIN PROCTER LLP
901 New York Avenue, NW
Washington, DC 20001
(202) 346-4000
jstull@goodwinlaw.com